Lacutamab
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Explore 59 assets in Primary Cutaneous T-Cell Non-Hodgkin Lymphoma →Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Innate Pharma
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03902184CT.gov IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma | — | Completed | — | — | — |
NCT02593045CT.gov Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lacutamab (this asset) | Innate Pharma | P2 | BB · 64 |
| (+)-Vincristine | Shanghai Jiao Tong University School of Medicine | P4 | BBB |
| Cyclophosphamide | Shanghai Jiao Tong University School of Medicine | P4 | BBB |
| Dexasone | National Cancer Institute (NCI) | P2 | BBB |
| Bexarotene | Case Comprehensive Cancer Center | P4 | BBB |
| Adriamycin | Falo, Louis, MD | P4 | BBB |
| Nivestim | City of Hope Medical Center | P4 | BBB |
| Fludarabine | National Cancer Institute (NCI) | P2 | BBB |
| Mogamulizumab | University of Michigan Rogel Cancer Center | P4 | BB |
+42 more in the Primary Cutaneous T-Cell Non-Hodgkin Lymphoma cohort
Other indications for Lacutamab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| T-Cell Non-Hodgkin Lymphoma | — | P2 | B · 57 |
| Mycosis Fungoides And Variants | — | P2 | B · 57 |
| Peripheral T-Cell Lymphoma, Not Otherwise Specified | — | P2 | CCC · 55 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Lacutamab in Primary Cutaneous T-Cell Non-Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lacutamab-primary-cutaneous-t-cell-non-hodgkin-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →